Screener
Bausch + Lomb BLCO Vision Care — Acquisitions (Note 5)
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch + Lomb in its filing.
Tagged under the XBRL concept us-gaap:GoodwillAcquiredDuringPeriod.
The source filing: Bausch + Lomb’s 10-Q, filed April 30, 2025.
- Filed
- Apr 30, 2025
- Fiscal quarter
- Q1 FY2025
- Calendar quarter
- Q1 2025
- Accession
- 0001860742-25-000008
| (in millions) | Vision Care | Pharmaceuticals | Surgical | Total |
|---|---|---|---|---|
| Balance, January 1, 2024 | $3,556 | $693 | $326 | $4,575 |
| Acquisitions (Note 5) | — | — | 29 | 29 |
| Foreign exchange | (27) | (49) | (5) | (81) |
| Balance, December 31, 2024 | 3,529 | 644 | 350 | 4,523 |
| Acquisitions (Note 5) | — | — | — | — |
| Foreign exchange | 6 | 33 | 5 | 44 |
| Balance, March 31, 2025 | $3,535 | $677 | $355 | $4,567 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Bausch + Lomb's vision care — acquisitions (note 5)?
- Bausch + Lomb (BLCO) reported vision care — acquisitions (note 5) of $0 in Q1 2025.
- What does vision care — acquisitions (note 5) mean?
- Tracks the capital deployed toward the purchase of external businesses, technologies, or product lines specifically within the Vision Care segment. This metric highlights the company's inorganic growth strategy and its ability to integrate new assets to expand its portfolio. Monitoring this helps investors assess how the firm scales its market share in the competitive vision care landscape.
Ask your AI about Bausch + Lomb's vision care — acquisitions (note 5).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude